UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004457
Receipt number R000003767
Scientific Title Transcranial Magnetic Stimulation in the treatment of major depression in cancer
Date of disclosure of the study information 2010/10/27
Last modified on 2011/04/18 17:52:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Transcranial Magnetic Stimulation in the treatment of major depression in cancer

Acronym

Transcranial Magnetic Stimulation in the treatment of major depression in cancer

Scientific Title

Transcranial Magnetic Stimulation in the treatment of major depression in cancer

Scientific Title:Acronym

Transcranial Magnetic Stimulation in the treatment of major depression in cancer

Region

Japan


Condition

Condition

Major depression

Classification by specialty

Psychiatry

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We aim to investigate the efficacy of transcranial magnetic stimulation (TMS) for depression in cancer patient.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

HAM-D

Key secondary outcomes

MADRS,VAS,CGI


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

TMS are performed with a frequency of 10Hz, trains of 6s, inter-train-intervals of 60s, 15 trains per session, 2 sessions per day on 10 working days.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients:
1)are now under treatment in National Cancer Center Hospital East
2)are at least 20 years old and over
3)have a moderate or severe major and minor depressive episode meeting DSM-4 criteria
4)are not able to take antidepressants

Key exclusion criteria

Patients:
1)who is not able to understand this study because of dementia, delirium, or other cognitive disorder
2)have brain metastasis
3)have neurological illness (e.g. epilepsy, meningitis)
4)had a history of convulsions
5)have a risk of epilepsy checked by the EEG
6)had previous neurosurgery with implants of metal
7)have pacemaker
8)attempt suicide or have the idea of suicide
9)fall into a stupor
10)have psychotic depression
11)had a history of failed response to electroconvulsive therapy
12)are depressed by organic illness or medication

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Asao Ogawa

Organization

Reserch Center for Innovative Oncology
National Cancer Center Hospital East

Division name

Psycho Oncology Division

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba JAPAN

TEL

04-7134-7013

Email



Public contact

Name of contact person

1st name
Middle name
Last name Asao Ogawa

Organization

Reserch Center for Innovative Oncology National Cancer Center Hospital East

Division name

Psycho Oncology Division

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba JAPAN

TEL

04-7134-7013

Homepage URL


Email

asogawa@east.ncc.go.jp


Sponsor or person

Institute

Reserch Center for Innovative Oncology
National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Grant from Health and Labor Sciences Reserch Grants, the third-term comprehensive control reserch for cancer

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター東病院(千葉県)


Other administrative information

Date of disclosure of the study information

2010 Year 10 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2008 Year 06 Month 13 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 10 Month 27 Day

Last modified on

2011 Year 04 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003767


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name